Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
SEOVF SERNOVA CORPORATION
0.598
-0.012-1.97%
YOY
Do not show
Hide blank lines
(Q3)2022/07/31(Q2)2022/04/30(Q1)2022/01/31(FY)2021/10/31
Financial Ratios
Efficiency Ratios TTM
ROIC
-48.42% -51.528% -72.82% -52.079% 20.6% -59.646% 58.71% -41.749%
ROE
-38.59% -50.869% -59.87% -51.579% 26.71% -59.047% 63.32% -43.246%
ROA
-42.43% -48.442% -58.73% -47.901% 25.7% -54.418% 58.41% -39.192%
Efficiency Ratios
ROE 5 Year Average
-- -- -- -- -- -- 3.8% -84.820%
ROA 5 Year Average
-- -- -- -- -- -- 3.78% -71.935%
Average 5 Years ROIC
-- -- -- -- -- -- 4.25% -81.599%
Profitability Ratios TTM
Financial Health Ratios
Long-Term Debt to Equity Ratio
-- 0.413% -- 0.878% -- 0.892% -94.2% 0.983%
Total Assets to Common Equity
2.35% 106.025% 7.68% 112.221% -0.62% 108.327% -23.09% 106.241%
Debt to Asset Ratio
-- 0.731% -- 1.416% -- 1.343% -91.73% 1.401%
Current Ratio
-34.64% 18.2576 -61.19% 9.305 26.22% 13.7586 265.96% 19.1936
Quick Ratio
-34.42% 18.1069 -61.58% 9.209 25.75% 13.5916 278.15% 19.1908
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- -- -- -- -- -- 0.000%
Currency Unit
CADCADCADCAD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Sernova Corp. is a clinical stage regenerative medicine company. It engages in the business of developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia and other diseases treated through replacement of proteins and hormones missing within the body. The firm also focuses in the manufacture and clinical evaluation of the cell pouch for insulin-dependent diabetes. The company was founded on August 19, 1998 and is headquartered in London, Canada.
CEO: Dr. Philip M. Toleikis
Market: Pink Market
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...